VBI Vaccines Inc. (VBIV)

NASDAQ: VBIV · IEX Real-Time Price · USD
0.622
+0.012 (1.90%)
Nov 29, 2023, 10:19 AM EST - Market open
1.90%
Market Cap 14.73M
Revenue (ttm) 8.12M
Net Income (ttm) -114.83M
Shares Out 23.69M
EPS (ttm) -11.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,906
Open 0.610
Previous Close 0.610
Day's Range 0.600 - 0.622
52-Week Range 0.450 - 21.000
Beta 1.87
Analysts Buy
Price Target 6.00 (+865.25%)
Earnings Date Nov 14, 2023

About VBIV

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in p... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Jeffery R. Baxter FCMA
Employees 190
Stock Exchange NASDAQ
Ticker Symbol VBIV
Full Company Profile

Financial Performance

In 2022, VBI Vaccines's revenue was $1.08 million, an increase of 71.47% compared to the previous year's $631,000. Losses were -$113.30 million, 62.4% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for VBIV stock is "Buy" and the 12-month stock price forecast is $6.0.

Price Target
$6.0
(865.25% upside)
Analyst Consensus: Buy
Stock Forecasts

News

VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...

9 days ago - Business Wire

VBI Vaccines Reports Third Quarter 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provid...

14 days ago - Business Wire

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...

4 weeks ago - Business Wire

VBI Vaccines' pan-coronavirus vaccine candidate produced broad protection against variants of concern

VBI Vaccines Inc. said Wednesday the first clinical data from a Phase I trial of a pan-coronavirus vaccine candidate produced broad and durable protection against variants of concern.

2 months ago - Market Watch

VBI Vaccines' Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...

2 months ago - Business Wire

VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...

2 months ago - Business Wire

VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”) today announced that its strategic hepatitis B (HBV) partner, Brii Biosciences (Brii Bio) (Stock code: 2137...

3 months ago - Business Wire

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased HBsAg seroconversion rate is stro...

3 months ago - PRNewsWire

Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

First patient dosed in a PEG-IFN -α  controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching pa...

Other symbols: VIR
3 months ago - PRNewsWire

VBI Vaccines Reports Second Quarter 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provid...

3 months ago - Business Wire

VBI Vaccines Announces Closing of Underwriters' Partial Exercise of Option to Purchase Additional Common Shares

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of diseas...

4 months ago - Business Wire

VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...

4 months ago - Business Wire

VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of diseas...

5 months ago - Business Wire

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive ...

5 months ago - PRNewsWire

VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of di...

5 months ago - Business Wire

VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of di...

5 months ago - Business Wire

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

Late-breaking data from BRII-835 + PEG-IFN- a  study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment  New data show mo...

Other symbols: VIR
5 months ago - PRNewsWire

VBI Vaccines Announces Results of Annual General Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of di...

5 months ago - Business Wire

VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...

5 months ago - Business Wire

VBI Vaccines Announces Poster Presentation at EASL 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...

6 months ago - Business Wire

VBI Vaccines Reports First Quarter 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provid...

7 months ago - Business Wire

VBI Vaccines Appoints Vaughn Himes to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...

7 months ago - Business Wire

VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split

VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct...

8 months ago - Market Watch

VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc.

8 months ago - Business Wire

VBI Vaccines Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provid...

9 months ago - Business Wire